Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07659639

Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer

LASERBLOOD is based on a biophotonic technology that can be used to predict the development of Pancreatic Ductal Adenocarcinoma (PDAC) in particular categories of subjects at risk (e.g. persons with diabetes, obese people, patients with Intraductal Papillary Mucinous Neoplasm [IPMN] or other cystic diseases of the pancreas, etc.) and at the same time offer the possibility of verifying the real effectiveness of the treatments to which affected patients are subjected.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Diabetes Diabetes Mellitus Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Glucose Metabolism Disorders IPMN, Pancreatic Metabolic Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Ductal, Lobular, and Medullary Neoplasms, Glandular and Epithelial Nutritional and Metabolic Diseases PDAC - Pancreatic Ductal Adenocarcinoma Pancreatic Diseases Pancreatic Intraductal Neoplasms Pancreatic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Fondazione Policlinico Universitario Campus Bio-Medico

Rome, Italy, 00128

Location status: Recruiting

Location contact

Damiano Caputo, MD

CONTACT

[email protected]

+3906225411257

About this study

LASERBLOOD is based on a biophotonic technology that can be used to predict the development of Pancreatic Ductal Adenocarcinoma (PDAC) in particular categories of subjects at risk (e.g. persons with diabetes, obese people, patients with Intraductal Papillary Mucinous Neoplasm [IPMN] or other cystic diseases of the pancreas, etc.) and at the same time offer the possibility of verifying the real effectiveness of the treatments to which affected patients are subjected.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

**Inclusion criteria for patients with PDAC and IPMN:**

  • No history of prior neoplastic diseases;
  • Adequate renal and hepatic function;
  • No hematologic disorders;
  • Age ≥ 18 years;
  • No active infections;
  • Written informed consent.

**Exclusion criteria:**

  • Severe pre-existing medical conditions, such as serious illnesses or other medical conditions that could negatively affect study outcomes or pose a high risk to the patient's health;
  • Ongoing therapies that could interfere with the study or alter the results.

Treatment and study plan

Diagnostic procedures

Diagnostic Test

Acquisition of biological material for bio-photonic technology analysis

Primary outcomes

  1. Diagnostic Accuracy of the Biophotonic Nanoparticle-Enabled Laser Blood Test (LASERBLOOD) for Detection of Pancreatic Ductal Adenocarcinoma (PDAC)

    Time frame: At baseline (time of enrollment), with reference standard diagnosis confirmed within 12 months

    Area Under the Receiver Operating Characteristic Curve (AUC-ROC), with 95% confidence interval, of fluorescence lifetime fingerprints obtained by biophotonic laser analysis of nanoparticle-protein corona complexes in plasma, in discriminating subjects with histologically confirmed Pancreatic Ductal Adenocarcinoma (PDAC) from subjects without PDAC (including healthy controls and patients with Intraductal Papillary Mucinous Neoplasm [IPMN]). The reference standard is histopathological diagnosis (on surgical specimen or endoscopic ultrasound-guided fine-needle aspiration/biopsy [EUS-FNA/B]) for PDAC and IPMN, and radiological/clinical assessment for healthy controls.

Secondary outcomes

  1. Sensitivity and Specificity of Fluorescence Lifetime (FL) Fingerprints for Pancreatic Ductal Adenocarcinoma (PDAC) Detection at Optimal Cut-off

    Time frame: At baseline (time of enrollment), with reference standard diagnosis confirmed within 12 months

    Sensitivity and specificity (percentage, with 95% confidence intervals) of fluorescence lifetime fingerprints in discriminating subjects with PDAC from subjects without PDAC, calculated at the optimal cut-off value determined by Youden's J index from the ROC analysis. Reference standard: histopathological diagnosis (surgical specimen or EUS-FNA/B) for PDAC and IPMN, radiological/clinical assessment for healthy controls.

  2. Correlation Between Fluorescence Lifetime (FL) Fingerprints and Clinical Stage of Pancreatic Ductal Adenocarcinoma (PDAC)

    Time frame: At time of PDAC diagnosis (within 12 months from enrollment)

    Spearman correlation coefficient (ρ), with 95% confidence interval, between fluorescence lifetime fingerprint values and clinical stage of PDAC at diagnosis, classified according to the 8th edition American Joint Committee on Cancer (AJCC) TNM staging system (Stage I-II: early disease; Stage III-IV: advanced disease).

  3. Mean Fluorescence Lifetime (FL) Values of Nanoparticle-Protein Corona Complexes in Plasma Samples, by Diagnostic Group

    Time frame: At baseline (time of enrollment), prior to any treatment

    Mean fluorescence lifetime values, in nanoseconds (ns), measured by biophotonic laser analysis of plasma samples incubated with nanoparticles, reported as mean ± standard deviation (SD) separately for each diagnostic group: Pancreatic Ductal Adenocarcinoma (PDAC), Intraductal Papillary Mucinous Neoplasm (IPMN), and healthy controls.

Study contacts

Contact information is provided by the study sponsor or research team.

Damiano Caputo, MD

CONTACT

[email protected]

+3906225418012

Sponsors and collaborators

Lead sponsor

Fondazione Policlinico Universitario Campus Bio-Medico

Other

Registry information

Acronym: LASERBLOOD

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
Jun 22, 2026
Registry last updated
Jun 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.